MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study
Academic Article
Publication Date:
2025
Short description:
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study / Venditti, Adriano; Kicinski, Michal; Audisio, Ernesta; Luppi, Mario; Lunghi, Monia; Foà, Robin; Candoni, Anna; Mengarelli, Andrea; Olivieri, Attilio; Imovilli, Annalisa; Musso, Maurizio; De Fabritiis, Paolo; Lanza, Francesco; Carella, Angelo Michele; Tafuri, Agostino; Del Principe, Maria Ilaria; Mancino, Alessandra; Suciu, Stefan; Giraut, Anne; Antunes, Stephanié; Wijermans, Pierre; Lübbert, Michael; Huls, Gerwin; Fazi, Paola; Vignetti, Marco; Buccisano, Francesco. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 1096-8652. - 100:9(2025), pp. 1691-1695. [10.1002/ajh.27763]
Iris type:
Articolo su rivista
Keywords:
AML; HSCT; decitabine; measurable residual disease; minimal residual disease (MRD)
List of contributors:
Venditti, Adriano; Kicinski, Michal; Audisio, Ernesta; Luppi, Mario; Lunghi, Monia; Foà, Robin; Candoni, Anna; Mengarelli, Andrea; Olivieri, Attilio; Imovilli, Annalisa; Musso, Maurizio; De Fabritiis, Paolo; Lanza, Francesco; Carella, Angelo Michele; Tafuri, Agostino; Del Principe, Maria Ilaria; Mancino, Alessandra; Suciu, Stefan; Giraut, Anne; Antunes, Stephanié; Wijermans, Pierre; Lübbert, Michael; Huls, Gerwin; Fazi, Paola; Vignetti, Marco; Buccisano, Francesco
Published in: